A股異動丨國藥股份(600511.SH漲近4% 年內將有6億支滅活疫苗獲批上市
格隆匯12月7日丨國藥股份(600511.SH漲近4%,報52元,盤中高見52.5元創逾5年來新高,總市值392億元。科研攻關組疫苗研發專班專家組副組長、中國工程院院士王軍志在第八次世界中西醫結合大會做《新冠肺炎疫苗和藥物研發進展》發言時表示,關於疫苗,未來一至兩週將有大消息公佈。年內將有6億支滅活疫苗獲批上市。全球新冠疫苗研發取得積極進展,海外主流發達國家已有訂單量測算接種率在65%-100%之間,我國2021年上半年有望迎來我國新冠疫苗落地期,大樣本調查顯示我國民眾接種意願較高,新冠疫苗商業化價值可期。國藥控股(1099.HK)微跌0.73%,國藥一致(000028.SZ)漲0.87%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.